A Common Antidepressant Shows Promise in Treating Methamphetamine Dependence

Why It Matters

It provides the first medication‑based option to curb meth use, giving clinicians a concrete tool to lessen health and societal harms.

Key Takeaways

• Mirtazapine reduced meth use by 2.2 days per month
• Trial involved 339 participants across six Australian outpatient clinics
• No new safety concerns; drowsiness and weight gain common
• First large, diverse study confirming mirtazapine’s modest efficacy
• Off‑label prescribing possible pending regulatory approval

Pulse Analysis

Methamphetamine addiction remains a global public‑health crisis, with an estimated 7.4 million users facing severe physical and mental consequences. Traditional interventions—counselling, detox, residential rehab—suffer from limited accessibility and high relapse rates, and no pharmacologic treatment has ever received regulatory approval. In this vacuum, repurposing existing drugs offers a pragmatic shortcut, leveraging known safety profiles to address an urgent unmet need. Mirtazapine, a widely prescribed antidepressant, entered the spotlight after early U.S. pilot studies hinted at reduced meth consumption, prompting a larger, more diverse investigation in Australia.

The Tina Trial enrolled 339 meth‑dependent adults across six outpatient clinics, randomising half to a daily 30 mg mirtazapine regimen and the remainder to placebo for twelve weeks. Participants entered the study using meth on roughly 22 of the past 28 days, providing a high‑risk baseline. Results showed a modest but statistically meaningful reduction: mirtazapine users reported an average of seven meth‑use days versus 4.8 days for placebo, translating to a 2.2‑day advantage per month. Importantly, the benefit persisted irrespective of baseline depression, suggesting a direct pharmacologic effect on reward pathways rather than merely alleviating mood symptoms. Safety data aligned with the drug’s established profile, with drowsiness and modest weight gain as the most common adverse events.

While the effect size is modest, the trial’s significance lies in establishing a proof‑of‑concept for medication‑assisted treatment of meth dependence. Off‑label prescribing is already feasible for clinicians familiar with mirtazapine, but formal regulatory endorsement would streamline insurance coverage and broader adoption. If subsequent studies replicate these findings, mirtazapine could become the cornerstone of a new therapeutic class, complementing behavioral interventions and potentially reducing the societal burden of meth‑related morbidity and mortality.